Pack size: 1 Injection  |  Price is for the whole Injection

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Mesna Disulfide

Form: Injection 400mg/4ml

Indication

Urothelial toxicity

Administration

IV Preparation Reconstitute w/ D5W, NS, dextrose/saline or LR to a final concentration of 20 mg/mL IV Administration IVP: bolus 15 min before ifosfamide Intermittent infusion over 15-30 min Continuous Infusion: may be added to ifosfamide/cyclophosphamide in infusion bag Additive compatibility w/ cyclophosphamide shown only in D5W & LR

Adult Dose

Intravenous Prophylaxis against urothelial toxicity With Ifosfamide 240 mg/sq.meter (if receiving 1.2 g/sq.meter ifosfamide dose) IVP 15 minutes before & 4 & 8 hours after ifosfamide admin OR 240 mg/sq.meter (if receiving 1.2 g/sq.meter ifosfamide dose) IVP 15 minutes before & 480 mg/sq.meter PO 2 & 6 hours after ifosfamide admin Adjust dose accordingly if ifosfamide dose changes Also given by alternative IVP regimens, intermittent infusion or continuous infusion-

Contraindication

Hypersensitivity to thiol-containing compounds.

Mode of Action

Mesna is used to prevent urothelial toxicity associated with oxazaphosphorine, ifosfamide or cyclophosphamide. It acts in the kidney; reacting with thiol groups of urotoxic metabolites (e.g. acrolein) of ifosfamide and cyclophosphamide. It is used as a mucolytic in the management of some respiratory tract conditions e.g. cystic fibrosis where other mucolytics have failed. It acts by reducing the viscosity of pulmonary secretions; the drug's free sulfhydryl group is thought to reduce disulfide linkages of mucoproteins.

Precaution

Protective effect applies only to the urinary tract; pregnancy, lactation. Patients with auto-immune disorders. IV formulation may contain benzyl alcohol as a preservative; avoid in neonates or infants. Instruct patients to seek medical attention if discolouration of urine occurs. During treatment, monitor urine for erythrocytes and haematuria. Maintain adequate hydration in all patients. Patients who vomit within 2 hr of oral dose should repeat dose or receive IV dose. Lactation: not known if excreted in breast milk, do not nurse

Introduction

$49

Uses of __NAME__

{'list': ['Ifosfamide-induced hemorrhagic cystitis']}

Side effects of __NAME__

{'tag': 'Common', 'list': ['Nausea', 'Headache', 'Lightheadedness', 'Lethargy', 'Abdominal pain', 'Flushing (sense of warmth in the face, ears, neck and trunk)', 'Diarrhea', 'Rash', 'Fever', 'Flu-like symptoms']}

How to use __NAME__

Your doctor or nurse will give you this medicine. Kindly do not self administer.

How __NAME__ works

__NAME__ helps to reduce the risk of inflammation and bleeding in the bladder, who receive ifosfamide (a medicine used to treat cancer).

Safety Advice

It is not known whether it is safe to consume alcohol with __NAME__. Please consult your doctor.

Safety Advice

__NAME__ is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.

Safety Advice

__NAME__ is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.

Safety Advice

__NAME__ may cause side effects which could affect your ability to drive. As patients undergoing treatment with __NAME__ may experience undesirable effects such as lightheadedness, lethargy, dizziness, and blurred vision which could affect the ability to drive.

Safety Advice

There is limited information available on the use of __NAME__ in patients with kidney disease. Please consult your doctor.

Safety Advice

There is limited information available on the use of __NAME__ in patients with liver disease. Please consult your doctor.